Advanced search
Publication Cover
Expert Opinion on Emerging Drugs Volume 11, 2006 - Issue 3
Submit an article Journal homepage
75
Views
12
CrossRef citations to date
0
Altmetric
Review

Emerging drugs to replace current leaders in first-line therapy for breast cancer

Michael C Cox Clinical Fellow, National Cancer Institute – National Institutes of Health, Breast Cancer Section, Medical Oncology Branch, Center for Cancer Research, Bethesda, MD, USA
,
Tu D Dan National Cancer Institute – National Institutes of Health, Medical Oncology Branch, Center for Cancer Research, 8901 Wisconsin Ave, Bldg 8, Rm 5101, Bethesda, MD, USA
&
Sandra M Swain Head, Breast Cancer Section, National Cancer Institute – National Institutes of Health, Medical Oncology Branch, Center for Cancer Research, 8901 Wisconsin Ave, Bldg 8, Rm 5101, Bethesda, MD, USA. [email protected]
Pages 489-501 | Published online: 29 Aug 2006

Bibliography

  • JEMAL A, SIEGEL R, WARD E et al.: Cancer Statistics, 2006. CA Cancer J. Clin. (2006) 56(2):106-130.
  • GLOBOCAN 2002: cancer incidence, mortality and prevalence worldwide. [program]. version 2.0 version. Lyon: IARCPress (2004).
  • MCPHERSON K, STEEL CM, DIXON JM: ABC of breast diseases. Breast cancer-epidemiology, risk factors, and genetics. BMJ (2000) 321(7261):624-628.
  • RIES L, EISNER M, KOSARY C et al.: SEER Cancer Statistics Review, 1975 – 2002. National Cancer Institute, Bethesda, MD, USA (2005).
  • MICHAELSON JS, SILVERSTEIN M, WYATT J et al.: Predicting the survival of patients with breast carcinoma using tumor size. Cancer (2002) 95(4):713-723.
  • EARLY BREAST CANCER TRIALISTS’ COLLABORATIVE GROUP: Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet (2005) 365(9472):1687-1717.
  • BONADONNA G, MOLITERNI A, ZAMBETTI M et al.: 30 years’ follow up of randomised studies of adjuvant CMF in operable breast cancer: cohort study. BMJ (2005) 330(7485):217.
  • BONADONNA G, VALAGUSSA P, MOLITERNI A, ZAMBETTI M, BRAMBILLA C: Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer – the results of 20 years of follow-up. N. Engl. J. Med. (1995) 332(14):901-906.
  • HOLMES FA, WALTERS RS, THERIAULT RL et al.: Phase II trial of taxol, an active drug in the treatment of metastatic breast cancer. J. Natl. Cancer Inst. (1991) 83(24):1797-1805.
  • NABHOLTZ JM, GLIGOROV J: The role of taxanes in the treatment of breast cancer. Expert Opin. Pharmacother. (2005) 6(7):1073-1094.
  • HENDERSON IC, BERRY DA, DEMETRI GD et al.: Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J. Clin. Oncol. (2003) 21(6):976-983.
  • MAMOUNAS EP, BRYANT J, LEMBERSKY BC et al.: Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: results from NSABP B-28. J. Clin. Oncol. (2005) 23(16):3686-3696.
  • CITRON M, BERRY DA, CIRRINCIONE C et al.: Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer And Leukemia Group B Trial 9741. J. Clin. Oncol. (2003) 21(8):1431-1439.
  • HUDIS C, CITRON M, BERRY D et al.: Five year follow-up of INT C9741: dose-dense (DD) chemotherapy (CRx) is safe and effective. San Antonio Breast Cancer Symposium 2005. San Antonio, TX, USA (2005):abstract 41.
  • MARTIN M, PIENKOWSKI T, MACKEY J et al.: Adjuvant docetaxel for node-positive breast cancer. N. Engl. J. Med. (2005) 352(22):2302-2313.
  • SLAMON DJ, CLARK GM, WONG SG et al.: Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science (1987) 235(4785):177-182.
  • SLAMON DJ, GODOLPHIN W, JONES LA et al.: Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science (1989) 244:707-712.
  • PEGRAM MD, KONECNY GE, O’CALLAGHAN C et al.: Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer. J. Natl. Cancer Inst. (2004) 96(10):739-749.
  • NAGATA Y, LAN KH, ZHOU X et al.: PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell (2004) 6(2):117-127.
  • COBLEIGH MA, VOGEL CL, TRIPATHY D et al.: Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J. Clin. Oncol. (1999) 17(9):2639-2648.
  • SLAMON DJ, LEYLAND-JONES B, SHAK S et al.: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med. (2001) 344(11):783-792.
  • ROMOND EH, PEREZ EA, BRYANT J et al.: Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N. Engl. J. Med. (2005) 353(16):1673-1684.
  • NABHOLTZ JM, REESE DM, LINDSAY MA, RIVA A: HER2-positive breast cancer: update on Breast Cancer International Research Group trials. Clin. Breast Cancer (2002) 3(Suppl. 2):S75-S79.
  • SLAMON DJ, EIERMANN W, ROBERT NJ et al.: Phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (AC-T) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (AC-TH) with docetaxel, carboplatin, and trastuzumab (TCH) in HER2 positive early breast cancer patients; BCIRG 006 study. San Antonio Breast Cancer Symposium 2005. San Antonio, TX, USA (2005):abstract 1.
  • PICCART-GEBHART MJ, PROCTER M, LEYLAND-JONES B et al.: Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N. Engl. J. Med. (2005) 353(16):1659-1672.
  • TEN TIJE AJ, VERWEIJ J, LOOS WJ, SPARREBOOM A: Pharmacological effects of formulation vehicles: implications for cancer chemotherapy. Clin. Pharmacokinet. (2003) 42(7):665-685.
  • MIELKE S, SPARREBOOM A, STEINBERG SM et al.: Association of paclitaxel pharmacokinetics with the development of peripheral neuropathy in patients with advanced cancer. Clin. Cancer Res. (2005) 11(13):4843-4850.
  • SCRIPTURE CD, SZEBENI J, LOOS WJ, FIGG WD, SPARREBOOM A: Comparative in vitro properties and clinical pharmacokinetics of paclitaxel following the administration of taxol(R) and paxene(R). Cancer Biol. Ther. (2005) 4(5):555-560.
  • IBRAHIM NK, DESAI N, LEGHA S et al.: Phase I and pharmacokinetic study of ABI-007, a cremophor-free, protein-stabilized, nanoparticle formulation of paclitaxel. Clin. Cancer Res. (2002) 8(5):1038-1044.
  • SPARREBOOM A, SCRIPTURE CD, TRIEU V et al.: Comparative preclinical and clinical pharmacokinetics of a cremophor-free, nanoparticle albumin-bound paclitaxel (ABI-007) and paclitaxel formulated in cremophor (taxol). Clin. Cancer Res. (2005) 11(11):4136-4143.
  • O’SHAUGHNESSY JA, TJULANDIN SA, DAVIDSON N et al.: ABI-007 (abraxane), a nanoparticle albumin-bound (nab) paclitaxel demonstrates superior efficacy versus taxol in MBC; a Phase III trial. 26th Annual San Antonio Breast Cancer Symposium 2003. San Antonio, TX, USA (2003):abstract 44.
  • BLUM J, SAVIN M, EDELMAN G et al.: Long term disease control in taxane-refractory metastatic breast cancer treated with nab paclitaxel. Proc. Am. Soc. Clin. Oncol. (2004):abstract 543.
  • LEE FY, BORZILLERI R, FAIRCHILD CR et al.: BMS-247550: a novel epothilone analog with a mode of action similar to paclitaxel but possessing superior antitumor efficacy. Clin. Cancer Res. (2001) 7(5):1429-1437.
  • YAMAGUCHI H, PARANAWITHANA SR, LEE MW et al.: Epothilone B analogue (BMS-247550)-mediated cytotoxicity through induction of Bax conformational change in human breast cancer cells. Cancer Res. (2002) 62(2):466-471.
  • ABRAHAM J, AGRAWAL M, BAKKE S et al.: Phase I trial and pharmacokinetic study of BMS-247550, an epothilone analog, administered intravenously on a daily schedule for five days. J. Clin. Oncol. (2003) 21(9):1866-1873.
  • MANI S, MCDAID H, HAMILTON A et al.: Phase I clinical and pharmacokinetic study of BMS-247550, a novel derivative of epothilone B, in solid tumors. Clin. Cancer Res. (2004) 10(4):1289-1298.
  • ZHUANG SH, AGRAWAL M, EDGERLY M et al.: A Phase I clinical trial of ixabepilone (BMS-247550), an epothilone B analog, administered intravenously on a daily schedule for 3 days. Cancer (2005) 103(9):1932-1938.
  • LOW JA, WEDAM SB, LEE JJ et al.: Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in metastatic and locally advanced breast cancer. J. Clin. Oncol. (2005) 23(12):2726-2734.
  • BROPHY DF, ISRAEL DS, PASTOR A et al.: Pharmacokinetic interaction between amprenavir and clarithromycin in healthy male volunteers. Antimicrob. Agents Chemother. (2000) 44(4):978-984.
  • PINTO AG, WANG YH, CHALASANI N et al.: Inhibition of human intestinal wall metabolism by macrolide antibiotics: effect of clarithromycin on cytochrome P450 3A4/5 activity and expression. Clin. Pharmacol. Ther. (2005) 77(3):178-188.
  • THOMAS E, TABERNERO J, FORNIER M et al.: A Phase II study of the epothilone B analog BMS-247550 in patients (pts) with taxane-resistant metastatic breast cancer. Proc. Am. Soc. Clin. Oncol. (2003):abstract 30.
  • ROCHE HH, CURE H, BUNNELL C et al.: A Phase II study of epothilone analog BMS-247550 in patients (pts) with metastatic breast cacner (MBC) previously treated with an anthracycline. Proc. Am. Soc. Clin. Oncol. (2003):abstract 69.
  • LEE F, CASTANEDA S, INIGO I et al.: Ixabepilone (BMS-247550) plus trastuzumab combination chemotherapy induces synergistic antitumor efficacy in HER2 dependent breast cancer and is accompanied by modulation of molecular reponse markers. Proc. Am. Soc. Clin. Oncol. (2005):abstract 561.
  • RUBIN EH, ROTHERMEL J, TESFAYE F et al.: Phase I dose-finding study of weekly single-agent patupilone in patients with advanced solid tumors. J. Clin. Oncol. (2005) 23(36):9120-9129.
  • FOLKMAN J: Tumour angiogenesis: therapeutic implications. N. Engl. J. Med. (1971) 285:1182-1186.
  • FOLKMAN J: Clinical applications of research on angiogenesis. N. Engl. J. Med. (1995) 333(26):1757-1763.
  • NICHOLSON B, THEODORESCU D: Angiogenesis and prostate cancer tumor growth. J. Cell Biochem. (2004) 91(1):125-150.
  • HOUCK KA, LEUNG DW, ROWLAND AM, WINER J, FERRARA N: Dual regulation of vascular endothelial growth factor bioavailability by genetic and proteolytic mechanisms. J. Biol. Chem. (1992) 267(36):26031-26037.
  • PARK JE, KELLER GA, FERRARA N: The vascular endothelial growth factor (VEGF) isoforms: differential deposition into the subepithelial extracellular matrix and bioactivity of extracellular matrix-bound VEGF. Mol. Biol. Cell (1993) 4(12):1317-1326.
  • BREM SS, JENSEN HM, GULLINO PM: Angiogenesis as a marker of preneoplastic lesions of the human breast. Cancer (1978) 41(1):239-244.
  • YOSHIJI H, GOMEZ DE, SHIBUYA M, THORGEIRSSON UP: Expression of vascular endothelial growth factor, its receptor, and other angiogenic factors in human breast cancer. Cancer Res. (1996) 56(9):2013-2016.
  • BROWN LF, BERSE B, JACKMAN RW et al.: Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in breast cancer. Hum. Pathol. (1995) 26(1):86-91.
  • SPEIRS V, ATKIN SL: Production of VEGF and expression of the VEGF receptors Flt-1 and KDR in primary cultures of epithelial and stromal cells derived from breast tumours. Br. J. Cancer (1999) 80(5-6):898-903.
  • KUREBAYASHI J, OTSUKI T, KUNISUE H et al.: Expression of vascular endothelial growth factor (VEGF) family members in breast cancer. Jpn. J. Cancer Res. (1999) 90(9):977-981.
  • HOAR FJ, LIP GY, BELGORE F, STONELAKE PS: Circulating levels of VEGF-A, VEGF-D and soluble VEGF-A receptor (sFIt-1) in human breast cancer. Int. J. Biol. Markers (2004) 19(3):229-235.
  • GASPARINI G: Prognostic value of vascular endothelial growth factor in breast cancer. Oncologist (2000) 5(Suppl. 1):37-44.
  • GASPARINI G, TOI M, BIGANZOLI E et al.: Thrombospondin-1 and -2 in node-negative breast cancer: correlation with angiogenic factors, p53, cathepsin D, hormone receptors and prognosis. Oncology (2001) 60(1):72-80.
  • RYDEN L, LINDERHOLM B, NIELSEN NH et al.: Tumor specific VEGF-A and VEGFR2/KDR protein are co-expressed in breast cancer. Breast Cancer Res. Treat. (2003) 82(3):147-154.
  • ZONDOR SD, MEDINA PJ: Bevacizumab: an angiogenesis inhibitor with efficacy in colorectal and other malignancies. Ann. Pharmacother. (2004) 38(7-8):1258-1264.
  • GORDON MS, MARGOLIN K, TALPAZ M et al.: Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J. Clin. Oncol. (2001) 19(3):843-850.
  • COBLEIGH MA, LANGMUIR VK, SLEDGE GW et al.: A Phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer. Semin Oncol (2003) 30(5 Suppl. 16):117-124.
  • MILLER KD, CHAP LI, HOLMES FA et al.: Randomized Phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J. Clin. Oncol. (2005) 23(4):792-799.
  • MILLER KD, WANG M, GRALOW J et al.: A randomized phase III trial of paclitaxel versus paclitaxel plus bevacizumab as first-line therapy for locally recurrent or metastatic breast cancer: a trial coordinated by the Eastern Cooperative Oncology Group (E2100). SABCS (2005):abstract 3.
  • SAKAMOTO KM: Su-11248 Sugen. Curr. Opin. Investig. Drugs (2004) 5(12):1329-1339.
  • MILLER K, BURNSTEIN H, ELIAS A et al.: Phase II study of SU-11248, a multitargeted receptor tyrosine kinase inhibitor (TKI), in patients (pts) with previously treated metastatic breast cancer (MBC). Proc. Am. Soc. Clin. Oncol. (2005):abstract 563.
  • ABRAMS TJ, LEE LB, MURRAY LJ, PRYER NK, CHERRINGTON JM: SU-11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer. Mol. Cancer Ther. (2003) 2(5):471-478.
  • O’FARRELL AM, ABRAMS TJ, YUEN HA et al.: SU-11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. Blood (2003) 101(9):3597-3605.
  • FAIVRE S, DELBALDO C, VERA K et al.: Safety, pharmacokinetic, and antitumor activity of SU-11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J. Clin. Oncol. (2006) 24(1):25-35.
  • SPICER J: Technology evaluation: pertuzumab, Roche/Genentech/Chugai. Curr. Opin. Mol. Ther. (2004) 6(3):337-343.
  • NAHTA R, HUNG MC, ESTEVA FJ: The HER-2-targeting antibodies trastuzumab and pertuzumab synergistically inhibit the survival of breast cancer cells. Cancer Res. (2004) 64(7):2343-2346.
  • AGUS DB, GORDON MS, TAYLOR C et al.: Phase I clinical study of pertuzumab, a novel her dimerization inhibitor, in patients with advanced cancer. J. Clin. Oncol. (2005) 23(11):2534-2543.
  • CORTES J, BASELGA J, KELLOKUMPU-LEHTINEN P et al.: Open label, randomized, Phase II study of pertuzumab (P) in patients (pts) with metastatic breast cacner (MBC) with low expression of HER2. Proc. Am. Soc. Clin. Oncol. (2005):abstract 3068.
  • XIA W, MULLIN RJ, KEITH BR et al.: Anti-tumor activity of GW-572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways. Oncogene (2002) 21(41):6255-6263.
  • CHU I, BLACKWELL K, CHEN S, SLINGERLAND J: The dual ErbB1/ErbB2 inhibitor, lapatinib (GW-572016), cooperates with tamoxifen to inhibit both cell proliferation- and estrogen-dependent gene expression in antiestrogen-resistant breast cancer. Cancer Res. (2005) 65(1):18-25.
  • SPECTOR NL, LIU L, GERARD C et al.: Combining lapatinib (GW-572016) with anti-erbB2 antibodies elicits synergistic apoptotic effects in erbB2 overexpressing breast cancer cells. Proc. Am. Soc. Clin. Oncol. (2005):abstract 557.
  • GOMEZ H, CHAVEZ MA, DOVAL DC et al.: Biomarker results from a Phase II randomized study of lapatinib (GW-572016) as first-line treatment for paitnes with ErbB2-amplified advanced or metastatic breast cancer. San Antonio Breast Cancer Symposium 2005. San Antonio, TX, USA (2005):abstract 1071.
  • VERSOLA M, BURRIS HA 3rd, JONES S et al.: Clinical activity of GW-572016 in EGF-1003 in patients with solid tumors. Proc. Am. Soc. Clin. Oncol. (2004): abstract 3047.
  • BURRIS HA 3rd, HURWITZ HI, DEES EC et al.: Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (gw572016), a reversible, dual inhibitor of epidermal growth factor receptor tyrosine kinases in heavily pretreated patients with metastatic carcinomas. J. Clin. Oncol. (2005) 23(23):5305-5313.
  • SPECTOR NL, XIA W, BURRIS HA 3rd et al.: Study of the biologic effects of lapatinib, a reversible inhibitor of ErbB1 and ErbB2 tyrosine kinases, on tumor growth and survival pathways in patients with advanced malignancies. J. Clin. Oncol. 23(11):2502-2512.
  • JONES SF, HAINSWORTH JD, SPIGEL DR et al.: A Phase I study of the dual kinase inhibitor GW-572016 in combination with paclitaxel (EGF-10009). Proc. Am. Soc. Clin. Oncol. (2004): abstract 2083.
  • STORNIOLO A, BURRIS HA 3rd, PEGRAM MD et al.: A Phase I, open-label study of lapatinib (GW-572016) plus trastuzumab; a clinically active regimen. Proc. Am. Soc. Clin. Oncol. (2005): abstract 559.
  • CHU Q, GOLDSTEIN LJ, MURRAY N et al.: A Phase I, open-label study of the safety, tolerability and pharmacokinetics of lapatinib (GW-572016) in combination with letrozole in cancer patients.Proc. Am. Soc. Clin. Oncol. (2005):abstract 3001.
  • BLACKWELL KL, KAPLAN EH, FRANCO SX et al.: A Phase II, open-label, multi-center study of GW-572016 in patients with trastuzumab-refractory metastatic breast cancer. Proc. Am. Soc. Clin. Oncol. (2005):abstract 3006.
  • GOMEZ HL, CHAVEZ MA, DOVAL DC et al.: A Phase II, randomized trial using the small molecule tyrosine kinase inhibitor lapatinib as a first-line treatment in patients with FISH-positive advanced or metastatic breast cancer. Proc. Am. Soc. Clin. Oncol. (2005):abstract 3046.
  • SMITH DA, BOWEN C, HERENDEEN JM et al.: An open-label, randomized, two-way crossover study to evaluate the potential inhibition of GW-572016 metabolism by ketoconazole. Proc. Am. Soc. Clin. Oncol. (2004): abstract 3071.
  • HERENDEEN JM, SMITH DA, STEAD A et al.: An open-label, fixed sequence, two period study to evaluate the potential induction of GW-572016 metabolism by carbamazepine. Proc. Am. Soc. Clin. Oncol. (2004):abstract 3081.
  • SAINSBURY JR, FARNDON JR, NEEDHAM GK, MALCOLM AJ, HARRIS AL: Epidermal-growth-factor receptor status as predictor of early recurrence of and death from breast cancer. Lancet (1987) 1(8547):1398-1402.
  • ROSKOSKI R Jr: The ErbB/HER receptor protein-tyrosine kinases and cancer. Biochem. Biophys. Res. Commun. (2004) 319(1):1-11.
  • BASELGA J, ALBANELL J, RUIZ A et al.: Phase II and tumor pharmacodynamic study of gefitinib in patients with advanced breast cancer. J. Clin. Oncol. (2005) 23(23):5323-5333.
  • VON MINCKWITZ G, JONAT W, FASCHING P et al.: A multicentre Phase II study on gefitinib in taxane- and anthracycline-pretreated metastatic breast cancer. Breast Cancer Res. Treat. (2005) 89(2):165-172.
  • PANWALKAR A, VERSTOVSEK S, GILES FJ: Mammalian target of rapamycin inhibition as therapy for hematologic malignancies. Cancer (2004) 100(4):657-666.
  • BOULAY A, RUDLOFF J, YE J et al.: Dual inhibition of mTOR and estrogen receptor signaling in vitro induces cell death in models of breast cancer. Clin. Cancer Res. (2005) 11(14):5319-5328.
  • KOVARIK JM, KAHAN BD, KAPLAN B et al.: Longitudinal assessment of everolimus in de novo renal transplant recipients over the first post-transplant year: pharmacokinetics, exposure-response relationships, and influence on cyclosporine. Clin. Pharmacol. Ther. (2001) 69(1):48-56.
  • RAYMOND E, ALEXANDRE J, FAIVRE S et al.: Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer. J. Clin. Oncol. (2004) 22(12):2336-2347.
  • CHAN S, SCHEULEN ME, JOHNSTON S et al.: Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR in heavily pretreated patients with locally advanced or metastatic breast cancer. J. Clin. Oncol. (2005) 23(23):5314-5322.
  • BASSO AD, MIRZA A, LIU G et al.: The farnesyl transferase inhibitor (FTI) SCH-6336 (lonafarnib) inhibits Rheb farnesylation and mTOR signaling. Role in FTI enhancement of taxane and tamoxifen anti-tumor activity. J. Biol. Chem. (2005) 280(35):31101-31108.
  • MARCUS AI, ZHOU J, O’BRATE A et al.: The synergistic combination of the farnesyl transferase inhibitor lonafarnib and paclitaxel enhances tubulin acetylation and requires a functional tubulin deacetylase. Cancer Res. (2005) 65(9):3883-3893.
  • ELLIS CA, VOS MD, WICKLINE M et al.: Tamoxifen and the farnesyl transferase inhibitor FTI-277 synergize to inhibit growth in estrogen receptor-positive breast tumor cell lines. Breast Cancer Res. Treat. (2003) 78(1):59-67.
  • CRUL M, DE KLERK GJ, SWART M et al.: Phase I clinical and pharmacologic study of chronic oral administration of the farnesyl protein transferase inhibitor R-115777 in advanced cancer. J. Clin. Oncol. (2002) 20(11):2726-2735.
  • LEBOWITZ PF, ENG-WONG J, WIDEMANN BC et al.: A Phase I trial and pharmacokinetic study of tipifarnib, a farnesyltransferase inhibitor, and tamoxifen in metastatic breast cancer. Clin. Cancer Res. (2005) 11(3):1247-1252.
  • JOHNSTON SR, HICKISH T, ELLIS P et al.: Phase II study of the efficacy and tolerability of two dosing regimens of the farnesyl transferase inhibitor, R-115777, in advanced breast cancer. J. Clin. Oncol. (2003) 21(13):2492-2499.
  • HENNESSY BT, SMITH DL, RAM PT, LU Y, MILLS GB: Exploiting the PI3K/AKT pathway for cancer drug discovery. Nat. Rev. Drug Discov. (2005) 4(12):988-1004.
  • EFFERTH T, VOLM M: Pharmacogenetics for individualized cancer chemotherapy. Pharmacol. Ther. (2005) 107(2):155-176.

Website

  • http://clinicaltrials.gov National Library of Medicine – National Institutes of Health.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.